On 1 March 2023, liraglutide (Victoza brand) became the second GLP-1 receptor agonist (GLP1RA) funded in Aotearoa New Zealand. This article and accompanying algorithm PDF have been developed to help prescribers through the process of starting dulaglutide or liraglutide in eligible patients with type 2 diabetes.
What's new with type 2 diabetes care in 2021?
Hover over the timeline to find the different chapters in this video.
Dr Ryan Paul is an academic endocrinologist at Waikato DHB and the University of Waikato. He is current president of the New Zealand Society of Endocrinology (NZSE) and an executive member of the New Zealand Society for the Study of Diabetes (NZSSD).
This resource will not be available after 30 June 2024 as He Ako Hiringa is shutting down. If your organisation would like to host this resource please contact admin@akohiringa.co.nz
This video was recorded from live webinars hosted by Mobile Health on 18 and 24 February 2021, attended predominantly by rural health professionals. The video has been edited for clarity.
This activity has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1 CME credit for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes.
Webinar outline
In this video, Dr Paul discusses the updates to type 2 diabetes care in 2021. The webinar covers:
- The updated treatment algorithm of type 2 diabetes in New Zealand.
- When and how to use SGLT2 inhibitors and GLP-1 receptor agonists.
- Who does and who does not meet the Special Authority criteria for funded SGLT2 inhibitors and GLP-1 receptor agonists.
- New recommendations for the screening and management of type 2 diabetes in Aotearoa New Zealand.
- Case discussion.
Downloadable empagliflozin patient information is available at:
- Healthify empagloflozin (Jardiance) - available in 11 languages
- Healthify Jardiamet
- Medsafe Jardiance
- Medsafe Jardiamet
Presentation slides
To view Dr Paul's slides from a similar presentation, click here.
Q&A
For a transcription of the Q&A from this webinar and a similar session run by The Goodfellow Unit, click here.
Timeline
- 00:00 - 01:36 Introduction
- 01:36 - 52:56 Dr Ryan Paul
- 52:56 - 1:05:43 Q&A and closing
Professional college endorsements
This activity has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1 CME credit for continuing professional development purposes (1 credit per learning hour). To claim your CPD credits, log in to your Te Whanake dashboard and record these activities under the appropriate learning category.
Related Articles
15 minutes to Read
20 March 2023